Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million
November 23, 2021 22:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop and launch the...
Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
November 23, 2021 16:30 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (“Outlook Therapeutics”), a late clinical-stage biopharmaceutical company working to develop the first...
Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference
November 13, 2021 11:00 ET
|
Outlook Therapeutics, Inc.
- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned BLA submission with U.S. FDA in Q12022 ...
Outlook Therapeutics to Present at the Virtual Investor Roundtable Event
November 10, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference
November 04, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases
November 03, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab
October 12, 2021 12:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
October 07, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
October 05, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
September 28, 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of...